ArticleLipids in health and disease2025
Integrated metabolic-inflammatory risk assessment: HbA1c/HDL-c and hsCRP-to-albumin ratios synergistically predict major adverse cardiovascular events in post-PCI STEMI patients.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Apoptotic markers and Dectin-1BMC cardiovascular disorders · 2026Article
- Data-driven glycolipid network phenotypes reveal a graded risk spectrum for cardiometabolic multimorbidity: a prospective study in middle-aged and older Chinese adults.Lipids in health and disease · 2026Article
- Suboptimal lipid management is associated with subclinical left ventricular dysfunction in type 2 diabetes mellitus patients with preserved ejection fraction: a cardiac magnetic resonance feature-tracking study.BMC cardiovascular disorders · 2026Article
- Association between HbA1c/HDL-C ratio and diabetic foot ulcer: a cross-sectional study based on the Han population in Northwest China.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study looked into how predictive in ST-segment elevation myocardial infarction (STEMI) is the high-sensitivity C-reactive protein-to-albumin ratio (hsCAR) as well as glycated hemoglobin to high-density lipoprotein cholesterol (HbA1c/HDL-c) ratio.
methodsThis retrospective cohort research was carried out on 1,177 patients having STEMI who were given percutaneous coronary intervention (PCI). For major adverse cardiovascular events (MACE), the independent and combined predictive values of the HbA1c/HDL-c ratio (threshold ≥ 6.61) and hsCAR (threshold ≥ 0.18) were assessed. MACE was an amalgamation of death from all causes, ischemia-induced revascularization, myocardial infarction not leading to death, heart failure hospitalization, and cerebrovascular events. The team used Cox regression models, causal mediation examination, and receiver operating characteristic curves to assess prognostic performance and mechanistic pathways, and compared them with the Global Registry of Acute Coronary Events (GRACE) risk score.
resultsThe interquartile range for follow-up was 79 to 672 days, with 461 median days. A raised HbA1c/HDL-c ratio (≥ 6.61) and hsCAR (≥ 0.18) independently predicted MACE, with 1.51 (95% confidence interval [CI]: 1.26-1.81; P < 0.001) as well as 1.84 (95% CI: 1.53-2.21; P = 0.005) hazard ratios (HRs), respectively. Combined use enhanced risk stratification, with the high HbA1c/HDL-c-high hsCAR group showing the highest risk (adjusted HR 2.19, 95% CI: 1.67-2.87; P < 0.001). Causal mediation examination revealed that coronary lesion complexity partially mediated these associations; the SYNergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) and the residual SYNTAX scores were responsible for accounting for 24.2%/17.7% of the hsCAR effect and 16.8%/25.2% of the HbA1c/HDL-c ratio effect, respectively. Compared with the individual markers or the GRACE risk score, the combined biomarker model demonstrated superior discriminatory capacity (area under the curve = 0.63, 95% CI = 0.60-0.66; P < 0.001), with significant improvement in integrated discrimination.
conclusionThe integration of HbA1c/HDL-c and hsCAR can significantly improve risk stratification in patients with STEMI, outperforming traditional scoring systems and assisting in the precise management of individuals at risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.